Ute Mühlhausen

Inhibition of O6-Methylguanine-DNA Methyltransferase by Glucose-Conjugated Inhibitors: Comparison with Nonconjugated Inhibitors and Effect on Fotemustine and Temozolomide-Induced Cell Death

Bernd Kaina, Ute Mühlhausen, Andrea Piée‐Staffa et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 54 citations

Synthesis of ¹³¹I-Labeled Glucose-Conjugated Inhibitors of <i>O</i>⁶-Methylguanine-DNA Methyltransferase (MGMT) and Comparison with Nonconjugated Inhibitors as Potential Tools for in Vivo MGMT Imaging

Ute Mühlhausen, Ralf Schirrmacher, Markus Piel et al. · Journal of Medicinal Chemistry · 2005 · 27 citations

Synthesis, radiofluorination and first evaluation of (±)‐[¹⁸F]MDL 100907 as serotonin 5‐HT_2A receptor antagonist for PET

Ute Mühlhausen, Johannes Ermert, Matthias M. Herth et al. · Journal of Labelled Compounds and Radiopharmaceuticals · 2008 · 24 citations

Chemistry, Positron Emission Tomography, Molecular Pharmacology +18

Synthesis of 2-amino-6-(2-[18F]fluoro-pyridine-4-ylmethoxy)-9-(octyl-β-d-glucosyl)-purine: a novel radioligand for positron emission tomography studies of the O6-methylguanine-DNA methyltransferase (MGMT) status of tumour tissue

Ralf Schirrmacher, Ute Mühlhausen, Björn Wängler et al. · Tetrahedron Letters · 2002 · 21 citations

Positron Emission Tomography, Engineering, Health Sciences +11

Synthesis, labelling and first evaluation of [¹⁸F]R91150 as a serotonin 5‐HT_2A receptor antagonist for PET

Ute Mühlhausen, Johannes Ermert, Heinz H. Coenen · Journal of Labelled Compounds and Radiopharmaceuticals · 2008 · 19 citations · Full text

Engineering, Psychotropic Medication, Pharmacotherapy +17